AOD-9604 is a modified fragment of human growth hormone developed for research into fat metabolism without reproducing all the biological actions of the full hormone. Laboratory and animal findings created interest in lipolysis, lipogenesis, and energy balance, but those findings must be separated from human clinical evidence and interpreted with care. The largest obesity trial did not demonstrate a significant weight-loss advantage over placebo, and AOD-9604 is not an FDA-approved weight-management medication.
What Is AOD-9604?
AOD-9604 is a synthetic, cyclic 16-amino-acid peptide based on residues 177–191 at the C-terminal end of human growth hormone, with an additional stabilizing tyrosine. It was investigated as a way to study selected fat-metabolism effects of growth hormone without administering the full hormone or assuming its complete growth-related activity.
The peptide is also described as Tyr-hGH177–191. Its two cysteine residues form a disulfide bond, an important structural feature that can also create stability, degradation, and aggregation concerns. AOD-9604 is therefore a genuine peptide fragment, but it is not full-length growth hormone and should not be represented as an approved obesity drug.
How Was AOD-9604 Developed?
AOD-9604 emerged from efforts to map different biological actions of human growth hormone to particular regions. Because the full hormone affects growth, IGF-1, glucose regulation, and lipid metabolism, investigators studied whether its C-terminal region might influence adipose tissue without reproducing broader somatotropic activity.
The goal was pharmacological separation, not proof of effectiveness. Much of the early evidence came from one connected Australian academic and commercial program, while independent replication and full publication of later clinical results remain limited.
How Does AOD-9604 Work?
The exact human mechanism remains unresolved. In preclinical models, researchers studied AOD-9604 in relation to lipolysis—the release of stored fatty acids—and lipogenesis, the synthesis and storage of fat. These are separate processes, and a change in either laboratory measurement does not automatically produce sustained body-weight reduction.
In obese mice, chronic treatment was associated with weight, fat-mass, lipolysis, and beta-3 adrenergic receptor RNA changes. Knockout experiments suggested that intact beta-3 adrenergic signaling contributed to some chronic effects, although AOD-9604 did not appear to act simply as a direct receptor agonist. Other experiments reported altered fat oxidation and energy expenditure, but no confirmed human molecular target has been identified.
For broader context on how research compounds are classified and evaluated before clinical use, see our guide to research peptides and evidence standards.
What Does Research Say About AOD-9604?
Laboratory Research
Laboratory studies examined adipose-tissue metabolism, receptor expression, cell proliferation, and growth-hormone-receptor interactions. FDA’s 2024 scientific review noted that AOD-9604 did not displace labeled growth hormone from growth-hormone receptors or stimulate proliferation in growth-hormone-receptor-expressing cells under the reported experimental conditions.
Those observations suggest that AOD-9604 does not reproduce full-length growth hormone signaling in that cell system. They cannot exclude every growth-related, glucose-related, or immune effect in a whole organism or establish long-term safety.
Animal Research
In obese Zucker rats, a 19-day study reported less body-weight gain, greater adipose lipolytic activity, and no adverse insulin-sensitivity change in a clamp assessment. These were findings in genetically obese rats, not people.
A 14-day study reported lower weight and fat measures in receptor-intact obese mice, while several chronic effects were absent in beta-3 receptor knockout animals. Acute energy-expenditure and fat-oxidation changes persisted in the knockout model, suggesting a mechanism more complex than one receptor pathway. These short studies cannot determine human effectiveness, adverse-event frequency, or long-term outcomes.
Human Clinical Research
A 2013 developer-associated paper summarized six randomized, double-blind, placebo-controlled studies involving 893 participants. The program included small single-exposure studies, a short repeated-exposure study, and two longer oral studies lasting up to 24 weeks. Most participants were adults with obesity.
An earlier 12-week study enrolled 300 adults and produced a modest signal in some analyses. FDA’s later review emphasized that the full methods and results were not published in a journal, that the dose response was not consistent, and that the reported differences had unclear therapeutic meaning. This limits confidence in the positive interpretation.
The decisive OPTIONS trial enrolled 536 adults with obesity and randomized 502 participants to several AOD-9604 groups or placebo alongside a dietitian-supervised diet and exercise program. It continued for 24 weeks, with the primary weight-loss evaluation at week 12. The trial did not show a statistically significant difference in weight loss between AOD-9604 and placebo at the primary endpoint. The developer subsequently terminated the obesity program because the findings did not support commercial viability.
This negative trial carries more weight than the earlier signal because it was larger and designed to test efficacy directly. Important details remain unavailable because the complete efficacy dataset was not published as a full peer-reviewed report.
Potential AOD-9604 Benefits in Research
The defensible “benefits” are research applications, not established health outcomes:
- Fat metabolism: investigating lipolysis, lipogenesis, and fat oxidation in experimental models.
- Adipose signaling: examining beta-adrenergic pathways and the limits of receptor-based explanations.
- Fragment biology: testing whether metabolic and growth-related signals can be separated structurally.
- Translation: studying why encouraging rodent mechanisms may fail in human efficacy trials.
Our existing AOD-9604 research overview provides additional background. Neither article should be read as a protocol or personal-use recommendation.
Does AOD-9604 Cause Weight Loss?
AOD-9604 has not been shown to produce reliable, clinically meaningful weight loss in humans. Preclinical studies reported changes in weight gain, adipose activity, and fat oxidation in rodents. A smaller human study generated an inconsistent signal, but the largest controlled obesity trial found no significant advantage over placebo at its primary endpoint.
Laboratory mechanisms often fail to translate because human energy balance depends on behavior, appetite, absorption, metabolism, compensatory signaling, tissue exposure, and many interacting pathways. A peptide can influence a biomarker without producing a durable clinical outcome. The evidence therefore does not support claims that AOD-9604 rapidly burns fat, works without lifestyle change, or guarantees weight loss.
What Are the Possible AOD-9604 Side Effects?
A dependable side-effect frequency cannot be established from the available evidence. The developer-associated human summary described overall tolerability as similar to placebo and reported no statistically significant differences in several monitored safety measures. That conclusion applies to the studied materials, routes, participants, and limited durations; it is not proof of general or long-term safety.
FDA’s independent review identified more uncertainty. In oral studies, serious events reported during trials included diarrhea, chest tightness, and several cancers. Intravenous studies included chest tightness and euphoria that investigators considered possibly related. An event occurring during a study is not automatically caused by the peptide, and FDA noted that causality for several serious reports was unclear.
The same FDA assessment found nonclinical signals involving bone findings in rats, possible liver toxicity in monkeys, and equivocal mutagenicity results. These signals do not prove the same harm in humans, but they weaken claims that the compound is risk-free and show why longer, better-characterized research would be necessary.
What Are the Main Safety Risks?
- Limited long-term evidence: the human program did not establish safety beyond several months of controlled exposure.
- Unknown interactions: reliable interaction studies with medicines, supplements, or health conditions are lacking.
- Route-specific gaps: FDA did not identify human information supporting nominated subcutaneous or transdermal uses.
- Immunogenicity: a synthetic peptide and its aggregates or impurities may provoke immune responses; available data do not resolve that risk across formulations and routes.
- Product quality: identity, peptide-related impurities, concentration, endotoxin control, degradation, and mislabeling may differ outside clinical research.
- Special populations: adequate evidence is absent for pregnancy, breastfeeding, children, older adults with multiple conditions, and people with significant liver, kidney, endocrine, or metabolic disease.
Does AOD-9604 Affect Growth Hormone or IGF-1?
AOD-9604 is derived from growth hormone but is not full-length growth hormone. Cell studies reviewed by FDA did not show the same growth-hormone-receptor binding or receptor-dependent proliferation observed with the complete hormone. In the summarized human trials, investigators reported no statistically significant differences in IGF-1 between AOD-9604 and placebo groups.
This means a growth-related or IGF-1 effect was not detected under those study conditions. It does not justify absolute claims that such effects can never occur at other exposures, with other formulations, through unstudied routes, or during longer use. FDA also noted limitations in the nonclinical support for some claims about IGF-1.
Is AOD-9604 FDA-Approved?
No. AOD-9604 is not an FDA-approved prescription drug for obesity, weight management, or another medical indication. FDA’s 2024 review stated that neither AOD-9604 free base nor its acetate form is a component of an FDA-approved drug and found insufficient evidence of obesity effectiveness.
FDA proposed against adding the related bulk substances to the section 503A Bulks List. In December 2024, the Pharmacy Compounding Advisory Committee voted 0–12 on whether they should be placed on that list. FDA’s current compounding-safety page continues to describe concerns involving immunogenicity, peptide-related impurities, active-ingredient characterization, limited safety information, and serious events with unclear causality.
Compounding review is different from formal drug approval. Availability from a clinic or online seller does not mean FDA has approved the product’s safety, effectiveness, manufacturing, labeling, or intended use.
What Remains Unknown About AOD-9604?
Evidence gaps include long-term human safety, meaningful weight-management effectiveness, pharmacokinetics for promoted non-oral routes, interactions, immune responses, special populations, and the molecular target responsible for the proposed metabolic activity. It is also unknown how prolonged pathway modification or online materials compare with the controlled research setting.
What Should Researchers Consider?
Research should document peptide form, sequence, disulfide status, purity, concentration, storage history, and degradation. Certificates of analysis should be supported by independent testing when identity or purity is central; sterility and endotoxin controls require separate validation where applicable.
Studies need appropriate controls, justified models, predefined outcomes, adverse-event monitoring, and transparent negative findings. Mechanistic endpoints, biomarkers, and clinically meaningful outcomes are not interchangeable. Human or animal work requires appropriate ethical, institutional, and regulatory oversight.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic, cyclic 16-amino-acid peptide derived from the C-terminal region of human growth hormone, with an added tyrosine. Researchers developed it to examine selected fat-metabolism effects without assuming the complete biological activity of full-length growth hormone. It is experimental and not an FDA-approved weight-loss medication.
Is AOD-9604 a growth hormone?
No. AOD-9604 is a modified fragment of human growth hormone, not the full hormone. Laboratory and human studies did not detect several hallmark growth-hormone effects under the conditions tested, including significant IGF-1 changes. Those limited observations do not prove that every growth-related effect is impossible under all conditions.
How is AOD-9604 studied in fat metabolism?
Researchers have studied AOD-9604 using laboratory assays and obese rodent models that measure lipolysis, lipogenesis, fat oxidation, adipose signaling, energy expenditure, and body-weight change. These models help investigate mechanisms but cannot establish that the peptide causes clinically meaningful human fat loss.
Does AOD-9604 cause weight loss?
Not reliably in humans. Rodent studies reported favorable metabolic and weight-related findings, while an early human study produced a limited signal. The largest controlled obesity trial did not show a statistically significant weight-loss advantage over placebo, and the obesity-development program was terminated.
What are the possible AOD-9604 side effects?
The frequency and full range of side effects remain uncertain. Trial events included gastrointestinal symptoms, chest tightness, euphoria, and serious diagnoses whose causal relationship was often unclear. FDA also identified nonclinical bone, liver, genotoxicity, immunogenicity, impurity, and characterization concerns. These findings do not support claims of complete safety.
Is AOD-9604 FDA-approved?
No. FDA has not approved AOD-9604 for obesity, weight management, or another medical use. Its evaluation as a possible bulk substance for compounding is a separate regulatory process and does not establish drug approval, clinical effectiveness, or equivalence to an approved medication.
Has AOD-9604 been studied in humans?
Yes, but the evidence has important limitations. Six controlled studies involving approximately 893 participants were summarized in a developer-associated safety paper. The longest lasted 24 weeks. The largest obesity trial failed its primary weight-loss endpoint, detailed efficacy results were not fully published, and long-term safety remains unestablished.
Conclusion
AOD-9604 is a modified growth-hormone fragment with a scientifically interesting history in fat-metabolism research. Laboratory and rodent studies reported changes in lipolysis, fat oxidation, adipose signaling, and weight-related measures, while limited human studies examined short-term tolerability and metabolic markers.
The central clinical result was negative: the largest obesity trial did not demonstrate significantly greater weight loss than placebo. AOD-9604 is not FDA-approved, and questions remain about long-term safety, interactions, immunogenicity, product quality, unstudied routes, and special populations. Further controlled and transparently reported research would be required before the peptide could be considered an effective or acceptably characterized human treatment.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Hormone Research. 2000;53(6):274–278. doi:10.1159/000053183. PMID: 11146367.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001;142(12):5182–5189. doi:10.1210/endo.142.12.8522. PMID: 11713213.
- Stier H, Vos E, Kenley D. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.” Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15. doi:10.4021/jem157w.
- Valentino MA, Lin JE, Waldman SA. “Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy.” Clinical Pharmacology & Therapeutics. 2010;87(6):652–662. doi:10.1038/clpt.2010.57. PMCID: PMC3136748.
- U.S. Food and Drug Administration. “FDA Briefing Document for AOD-9604-Related Bulk Drug Substances.” Pharmacy Compounding Advisory Committee Meeting. December 4, 2024. Direct FDA document.
- U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” Updated 2026. Direct FDA page.
